Video Latest - ecancer

Denosumab vs zoledronic acid for bone disease in newly diagnosed multiple myeloma

Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece

3 Mar 2017

Bone disease and management of myeloma complications

Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece

3 Mar 2017

Monoclonal antibodies in multiple myeloma

Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain

2 Mar 2017

Promising myeloma agents in phase II trials

Dr Ruben Niesvizky - New York Presbyterian Hospital-Weill Cornell Medical Center, New York, USA

2 Mar 2017

Ongoing transplant phase III trials for myeloma

Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA

2 Mar 2017

Post autologous transplant therapies in high risk multiple myeloma: StaMINA trial update

Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA

2 Mar 2017

Updates from ASPIRE and ENDEAVOR: Multicenter phase III studies of carfilzomib for relapsed/refractory multiple myeloma

Dr David Siegel - John Theurer Cancer Center, Hackensack, USA

$Updates from ASPIRE and ENDEAVOR: Multicenter phase III studies of carfilzomib for relapsed/refractory multiple myeloma ( Dr David Siegel - John Theurer Cancer Center, Hackensack, USA )$

2 Mar 2017

Pomalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma

Dr David Siegel - John Theurer Cancer Center, Hackensack, USA

$Pomalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma ( Dr David Siegel - John Theurer Cancer Center, Hackensack, USA )$